Transforming jellyfish biomass into smart wound-care products utilizing non-mammalian collagen and glycoproteins to enhance healing and hydration, with proven clinical trial success in modular wound dressings.
The innovative use of jellyfish biomass in wound and scar healing products creates a novel opportunity in the biomedical and cosmetic industries. By leveraging the non-mammalian collagen and glycoproteins found in jellyfish, this technology offers advanced solutions such as gels, masks, and sprays that enhance healing and provide moisturizing benefits. These products are particularly effective due to the collagen's role in wound healing and the glycoproteins' hydrating properties. Furthermore, jellyfish are an abundant, renewable resource, turning an ecological challenge into a valuable asset.
Key features:
This technology is currently at TRL 4, having successfully passed clinical trials for a modular wound dressing. Future validations will focus on developing raw formulations for specific applications, testing biocompatibility, and initiating regulatory processes.
Tel Aviv University is one of Israel’s largest comprehensive public research universities with a broad academic portfolio and strong research culture. Located in Tel Aviv’s dense startup and multinational R&D corridor, it engages industry through sponsored research, shared-use facilities, executive education, and access to top talent. A dedicated technology transfer company manages IP, licensing, and venture creation, complemented by entrepreneurship programs and proof‑of‑concept support; clinical collaborations across the city’s healthcare ecosystem enable translation. Research is supported by competitive national agencies and international programs, including the Israel Innovation Authority and European research frameworks. Corporate engagement offices streamline scoping and agreements, giving partners clear entry points.